# US 2006/0052377 A1 · Benzyl morpholine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052377 A1
- Document ID: US20060052377A1
- Status: Published application
- Kind: A1
- Application number: 10/524,798
- Filed: 2003-08-18
- Published: 2006-03-09
- Earliest claimed: 2002-08-23
- Assignees: Eli Lilly and Company
- Inventors: Barry Clark; Peter, Thaddeus Gallagher; Helen, Louise Haughton
- Web page: https://patentgrep.com/patent/US20060052377A1

## CPC

- C07D 265/30: not condensed with other rings
- A61P 25/24: Antidepressants
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of formula (I) (I) wherein R is H; Ar is an aromatic group selected from phenyl; X is a phenyl group; R′ H or C1-C4 alkyl; each R1 is independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

A compound of formula (I)
wherein
R is H;
Ar is an aromatic group selected from unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substitutents selected from C1-C4 alkyl, O(C1-C4 alkyl), S(C1-C4 alkyl), halo, and phenyl optionally substituted with halo, C1-C4 alkyl or O(C1-C4 alkyl);
X is unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents selected from C1-C4 alkyl, O(C1-C4 alkyl), and halo;
R′ is h or C1-C4 alkyl;
each R1 is independently H or C1-C4 alkyl;
wherein each above-mentioned C1-C4 alkyl group is optionally substituted with one or more halo atoms;
or a pharmaceutically acceptable salt thereof:

### Claim 2 (depends on 1)

A compound as claimed in claim 1, represented by formula II:
in which R2 and R3 are each independently selected from H, C1-C4 alkyl, O(C1-C4 alkyl),
S(C1-C4 alkyl), halo, and phenyl; and
R4 is selected from H, C1-C4 alkyl, O(C1-C4 alkyl) and halo;
wherein each above-mentioned C1-C4 alkyl group is optionally substituted with one or more halo atoms;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

A compound as claimed in claim 2, wherein R2 is selected from C1-C2 alkyl, O(C1-C2 alkyl), S(C1-C2 alkyl), Cl and F wherein each above-mentioned C1-C2 alkyl group is optionally substituted with one or more halo atoms.

### Claim 4 (depends on 2, 3)

A compound as claimed in claim 2 or claim 3, wherein R3 is selected from H, Me and Cl.

### Claim 5 (depends on 2, 4)

A compound as claimed in any one of the claims 2 to claim 4, wherein R is selected from H, C1-C2 alkyl, O(C1-C2 alkyl), Cl and F wherein each above-mentioned C1-C2 alkyl group is optionally substituted with one or more halo atoms.

### Claim at position 6

6-9. (canceled)

### Claim 10 (depends on 1, 2)

A method for selectively inhibiting the reuptake of serotonin and norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in claim 1 or 2.

### Claim 11 (depends on 1, 2)

A method for treating a disorder associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in claim 1 or 2.

### Claim 12 (depends on 11)

A method as claimed in claim 11, wherein the disorder is selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation and pain.

### Claim 13 (depends on 11)

A method as claimed in claim 11, wherein the disorder is selected from depression, stress urinary incontinence and pain.

### Claim 14 (depends on 11)

A method as claimed in claim 11, wherein the disorder is pain.

### Claim 15 (depends on 1, 2)

A composition comprising a compound as claimed in claim 1 or 2 together with a pharmaceutically acceptable diluent, excipient or carrier.
